INCOG BioPharma investing additional $125M on Fishers campus
The expansion plan includes construction of a 100,000-square-foot building on its corporate campus and the addition of 100 jobs.
Pharmaceutical
Articles
Stevanato commits to paying Fishers employees a living wage
Stevanato, an Italian-based life sciences company that makes glass vials and syringes for pharmaceuticals, has committed to paying employees at its new Fishers facility no less than $70,000 annually.
UPDATE: FDA approves Lilly drug that can modestly slow Alzheimer’s disease
Eli Lilly’s drug—Kisunla, the brand name for donanemab—is one of the few treatments developed for Alzheimer’s that modifies the underlying disease and will join just one other drug, Leqembi, on the commercial market.
The Supreme Court rejects a nationwide opioid settlement with OxyContin maker Purdue Pharma
The decision also could affect other major bankruptcies, including the $2.4 billion bankruptcy plan for the Boy Scouts of America that has been approved by a federal judge, lawyers said.
Weight-loss-drug frenzy lures rich Indians to brave the gray market
The race to score blockbuster weight-loss drugs like Eli Lilly’s Mounjaro and Zepbound is pushing one of the world’s largest population of people with obesity to creative lengths.
Lilly files suit against more spas, weight-loss centers selling knockoff version of its popular drugs
The Indianapolis-based drugmaker said Thursday it was taking legal action against at least six additional medical spas and weight loss centers that it claimed are selling counterfeit and compounded versions of tirzepatide, the active ingredient in Lilly’s diabetes treatment Mounjaro and weight-loss treatment Zepbound.
Fishers approves incentives agreement for pharmaceutical logistics company
A Philadelphia-based company involved in drug delivery and logistics is working with the city of Fishers on an economic development deal that could result in a $40 million investment and 350 new jobs.
Lilly and subsidiary Point Biopharma accused of patent infringement of cancer drugs
At issue is whether a drug developed by Point Biopharma, based in Indianapolis, infringed on a patent issued in 2020 and assigned to Purdue Research Foundation.
Drug shortages keep growing. Older, injectable medicines among most vulnerable.
Total active shortages hit an all-time high of 323 in this year’s first quarter, according to the University of Utah Drug Information Service. That’s up about 86% since 2017.
Michigan’s largest insurer to drop weight-loss drug coverage
Obesity drugs such as Novo’s Wegovy and Lilly’s Zepbound are exploding in popularity. But with list prices of $1,000 a month or more, insurers are balking at the prices and trying to limit how widely they’re used.
Lilly Alzheimer’s drug that can slow disease gets backing from FDA advisers
If the FDA agrees with the panel’s recommendation, the drug, donanemab, would only be the second Alzheimer’s drug cleared in the U.S. that’s been shown to convincingly slow cognitive decline and memory problems due to Alzheimer’s.
Lilly hopes for positive FDA news on Alzheimer’s drug as stock sets new high
Lilly officials have said they are “incredibly confident” in the drug’s potential and the fact that it “offers very meaningful benefits to people with early symptomatic Alzheimer’s disease.”
Lilly CFO Ashkenazi leaving to take job at Google parent Alphabet
Anat Ashkenazi was Lilly’s third-highest paid executive last year. She has worked at the company for 23 years, including as chief financial officer since 2021.
Britain poised to offer Eli Lilly’s weight-loss drug to patients
If the guidance is confirmed, Mounjaro will challenge the dominance of Novo’s Wegovy in the United Kingdom.
Weight-loss drug shortages lead to tracker from startup
Ro’s tracker is the latest in the frenzy surrounding weight-loss drugs made by Novo Nordisk and Indianapolis-based Eli Lilly and Co.
Lilly’s huge expansion plan took place at record speed to reduce bottlenecks for Mounjaro, Zepbound
The company said the site footprint will not expand, but the company will fill in the property with more buildings and equipment. Manufacturing capacity will almost triple there.
Lilly to invest another $5.3B in Lebanon site to meet overwhelming demand for Mounjaro, Zepbound
Lilly said the new investment will allow it to hire 200 more workers at the complex, including engineers, scientists, and lab technicians, for a total of 900 full-time workers when it is fully operational.
China clears Eli Lilly’s weight-loss drug, only for diabetes now
The pharmaceutical weight-loss market is predicted to reach at least $100 billion by 2030, according to Goldman Sachs.
Drugmaker Novartis to expand nuclear medicine factory near airport, creating 55 jobs
Novartis Manufacturing LLC told a committee of the City-County Council on Monday evening that it plans to spend up to $125 million to construct and equip a 79,000-square-foot-building for radiopharmaceutical manufacturing and distribution on the city’s west side.
Hims debuts $199 weight-loss shots, takes aim at Lilly’s Zepbound
Hims can offer the prescription weight-loss drugs because U.S. regulators have rules that allow pharmacies to make copycat versions of drugs in shortage, a practice that’s known as “compounding.”